| Literature DB >> 32903649 |
Luis Morenilla1, Gonzalo Márquez1, José Andrés Sánchez1, Olalla Bello2, Virginia López-Alonso3, Helena Fernández-Lago4, Miguel Ángel Fernández-Del-Olmo5.
Abstract
BACKGROUND: The reviewed studies on center of pressure (COP) displacement in Parkinson's disease (PD) subjects show important methodological differences and contradictory results with regard to healthy subjects. The dual-task paradigm method has been used to examine cognitive prioritization strategies to control concurrent postural and cognitive tasks. The motor requirements, such as pronouncing words, involved in the cognitive tasks used in double-task conditions could be related to the heterogeneity of the results. RESEARCHEntities:
Keywords: Parkinson’s disease; balance; dual-task; postural sway; upright stance
Year: 2020 PMID: 32903649 PMCID: PMC7438725 DOI: 10.3389/fpsyg.2020.01256
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Participant characteristics data.
| Age (years) | Weight (kg) | Height (cm) | MMSE | ||
| PD patients | 25 | 57.6 ± 11.5 | 78.7 ± 14.9 | 166.8 ± 7.7 | 29.6 ± 0.8 |
| 10♀/15♂ | |||||
| Controls | 20 | 59.1 ± 13.3 | 72 ± 9.7 | 163.8 ± 7.9 | 29.4 ± 0.9 |
| 10♀/10♂ | |||||
| 0.695 | 0.078 | 0.210 | 0.435 |
Clinical characteristics of the PD patients’ group.
| Patient number | Sex | Age | Disease duration (years) | H&Y (1 – 5) | UPDRS-III (0 – 56) | Medication per day (mg) | LED (mg) |
| 1 | F | 40 | 1 | 1 | 4 | Levodopa/Carbidopa 300/75, Rasagiline 1, Rotigotine 6 | 580 |
| 2 | M | 66 | 1,5 | 1 | 7 | Levodopa/Carbidopa 375/37.5, Rasagiline 1 | 475 |
| 3 | M | 37 | 2 | 1 | 9 | Rasagiline 1 | 100 |
| 4 | M | 70 | 2 | 1 | 8 | Levodopa/Carbidopa 375/37.5, Rasagiline 1 | 475 |
| 5 | M | 56 | 2 | 1,5 | 12 | Pramipexole 2.1 | 210 |
| 6 | F | 46 | 1 | 2 | 23 | Levodopa/Carbidopa 150/37.5, Rasagiline 1, Pramipexole 3.15 | 565 |
| 7 | F | 39 | 2,3 | 2 | 18 | Levodopa/Carbidopa 375/93.75, Entacapone 600, Rasagiline 1 | 673 |
| 8 | M | 45 | 3 | 2 | 11 | Levodopa/Carbidopa 225/56.25, Entacapone 600, Rasagiline 1, Rotigotine 4 | 643 |
| 9 | M | 67 | 3 | 2 | 15 | Levodopa/Benserazide 500/125, Rasagiline 1, Pramipexole 2.64 | 864 |
| 10 | M | 62 | 4 | 2 | 12 | Levodopa/Carbidopa 150/37.5, Entacapone 600, Pramipexole 3.15 | 663 |
| 11 | M | 50 | 5 | 2 | 19 | Levodopa/Carbidopa 300/75, Rasagiline 1, Rotigotine 8 | 640 |
| 12 | F | 51 | 5 | 2 | 36 | Levodopa/Benserazide 600/150 | 600 |
| 13 | M | 58 | 6 | 2 | 23 | Levodopa/Carbidopa 500/125, Rasagiline 1, Rotigotine 4 | 720 |
| 14 | M | 60 | 6 | 2 | 12 | Levodopa/Carbidopa 800/200, Entacapone 800, Pramipexole 3.15 | 1379 |
| 15 | M | 55 | 6 | 2 | 23 | Levodopa/Carbidopa 225/56.25, Entacapone 600, Rasagiline 1, Ropinirole 20 | 923 |
| 16 | F | 61 | 6 | 2 | 23 | Levodopa/Carbidopa 500/50, Pramipexole 3.15 | 815 |
| 17 | M | 60 | 7 | 2 | 13 | Levodopa/Carbidopa 500/125, Ropinirole 12, Trihexyphenidyl 2 | 740 |
| 18 | M | 63 | 8 | 2 | 21 | Levodopa/Carbidopa 750/187.5, Entacapone 1000, Rasagiline 1, Pramipexole 3.15 | 1580 |
| 19 | M | 68 | 1 | 2,5 | 16 | Levodopa/Carbidopa 150/37.5, Entacapone 600, Rasagiline 1 | 448 |
| 20 | M | 80 | 6 | 2,5 | 29 | Levodopa/Benserazide 500/125 | 500 |
| 21 | F | 46 | 6 | 2,5 | 23 | Levodopa/Carbidopa 200/50, Levodopa/Benserazide 550/137.5, Rotigotine 6, Rasagiline 1, Amantadine 200 | 1230 |
| 22 | F | 54 | 6 | 2,5 | 25 | Levodopa/Carbidopa 400/100, Entacapone 800, Rotigotine 12 | 1024 |
| 23 | F | 66 | 12 | 2,5 | 12 | Levodopa/Carbidopa 200/50, Levodopa/Benserazide 550/137.5, Rotigotine 6, Rasagiline 1, Amantadine 200 | 1230 |
| 24 | F | 62 | 2 | 3 | 31 | Levodopa/Carbidopa 600/150, Entacapone 600, Rotigotine 6, Pramipexole 3.15 | 1293 |
| 25 | F | 79 | 7 | 3 | 35 | Levodopa/Carbidopa 400/50, Pramipexole 0.18 | 418 |
| Mean | 57,6 | 4,42 | 2 | 18,4 | 751,52 | ||
| SD | 11,5 | 2,71 | 0,56 | 8,69 | 358,63 |
COP displacement variable data recorded in the four test conditions for PD patients and control groups.
| Control group | PD patient group | |||||||
| ST | DT | ST | DT | |||||
| OE | CE | OE | CE | OE | CE | OE | CE | |
| Trace length (mm) | 1433.42 ± 311.66 | 1535.72 ± 270.34 | 1460.89 ± 309.23 | 1570.06 ± 334.99 | 1484.12 ± 316.47 | 1704.42 ± 407.54 | 1519.86 ± 424.89 | 1727.27 ± 577.12 |
| Area (mm2) | 1958.87 ± 626.61 | 2291.25 ± 1110.07 | 1821.46 ± 825.60 | 2007.67 ± 1136.01 | 3030.70 ± 1254.25 | 4011.22 ± 1637.79 | 2683.34 ± 979.07 | 3473.88 ± 1371.51 |
| Radius (mm) | 4.81 ± 1.67 | 5.24 ± 1.98 | 4.34 ± 4.31 | 4.31 ± 1.45 | 6.75 ± 2.35 | 7.69 ± 1.95 | 5.78 ± 1.38 | 6.43 ± 1.33 |
| A-P sway (mm) | 40.49 ± 26.89 | 46.08 ± 24.61 | 44.88 ± 28.65 | 40.86 ± 30.90 | 69.28 ± 31.48 | 67.49 ± 31.29 | 64.06 ± 35.65 | 63.26 ± 24.22 |
| M-L sway (mm) | 6.85 ± 4.91 | 5.74 ± 4.67 | 4.49 ± 4.69 | 4.60 ± 3.90 | 6.05 ± 4.47 | 6.60 ± 5.31 | 7.35 ± 3.85 | 6.47 ± 4.33 |
| A-P range (mm) | 22.81 ± 7.55 | 28.78 ± 9.90 | 21.67 ± 8.58 | 23.43 ± 7.94 | 31.32 ± 13.25 | 36.98 ± 9.46 | 27.43 ± 8.38 | 31.77 ± 8.69 |
| M-L range (mm) | 15.71 ± 5.42 | 17.41 ± 8.51 | 14.20 ± 5.76 | 15.62 ± 7.33 | 23.74 ± 7.25 | 29.81 ± 9.12 | 21.44 ± 5.26 | 28.05 ± 9.12 |
ANOVA results for COP displacement variables.
| Group | Vision | Group × Vision | Task | Group × Task | Vision × Task | Group × Vision × Task | |
| Trace length (mm) | ns | ns | ns | ns | ns | ns | ns |
| Area (mm2) | F1,42 = 19.203 | ns | F1,42 = 6.637 | ns | ns | ns | ns |
| Radius (mm) | F1,42 = 25.822 | ns | ns | F1,42 = 6.128 | ns | ns | ns |
| A-P sway (mm) | F1,42 = 8.304 | ns | ns | ns | ns | ns | ns |
| M-L sway (mm) | ns | ns | ns | ns | F1,42 = 4.454 | ns | ns |
| A-P range (mm) | F1,42 = 13.832 | ns | ns | ns | ns | ns | ns |
| M-L range (mm) | F1,42 = 29.068 | ns | F1,42 = 9.938 | ns | ns | ns | ns |
FIGURE 1Vision and task effects on COP displacement variables. Changes appeared in the total area covered by the COP displacement and in the M-L range of COP sway (mean values with standard error bars) during a dual-task performed from the open eyes condition to closed eyes, for PD patients (**p < 0.0001) and controls. Changes (mean values with standard error bars) were recorded in the radius of COP sway for all participants (*p < 0.05) as well as in the M-L sway of COP for controls (*p < 0.05) and PD patients, from single-task (standing task only) to dual-task (standing plus cognitive task) conditions. PD, Parkinson’s disease; OE, open eyes; CE, closed eyes; ST, single task; DT, dual-task.
FIGURE 2Task effect on cognitive performance. Changes appeared in cognitive task performance (mean values with standard error bars) from single-task conditions (cognitive task conducted by seated participants) to the dual-task with open eyes (for PD patients, *p = 0.039, and controls, **p = 0.009) and the dual-task with closed eyes. Differences were recorded between the groups in cognitive task performance in the dual-task with open eyes condition (**p < 0.01). PD, Parkinson’s disease; BL, cognitive baseline; DTOE, dual-task open eyes; DTCE, dual-task closed eyes.